Qualigen therapeutics appoints shishir sinha to lead diagnostics division following promotion to senior vice president

Carlsbad, calif., april 29, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, announces today that it has appointed shishir sinha, the company's newly promoted senior vice president and current chief operating officer, to lead the company's diagnostics division.
QLGN Ratings Summary
QLGN Quant Ranking